The clinical application of RNA-targeting therapeutics is frequently limited by unpredictable innate immune activation, which can affect both safety and efficacy. Therefore, the development of robust platforms to assess drug-induced innate immune responses is crucial for the early evaluation of these compounds. Here, we developed a whole-blood assay for the assessment of innate immune activation induced by RNA-targeting therapeutics. The platform was evaluated using Food and Drug Administration (FDA)-approved drugs and compounds previously withdrawn or discontinued due to immune-related adverse effects. The assay showed qualitative concordance with known clinical immunogenicity profiles, with compounds associated with immune-related toxicities inducing stronger immune responses than therapeutics with established clinical safety records. Integrated cytokine analysis identified IL-8 and CXCL10 as candidate biomarkers of immune activation, enabling compound characterization according to their immunostimulatory profiles. Parallel studies in murine whole blood provided cross-species comparisons highlighting species-specific differences in innate immune responses. To investigate nucleic acid-sensing pathways contributing to innate immune activation, we applied the assay to transgenic mouse strains deficient in key signaling molecules, including MAVS, MyD88, TRIF, and UNC93B1, supporting their involvement in RNA-induced inflammatory responses. Collectively, our assay supports comparative profiling of innate immune activation to RNA-targeting therapeutics, with potential utility in the early evaluation of next-generation RNA therapies.
Development of a whole-blood assay for assessing innate immune activation induced by RNA-targeting therapeutics
Grasso F.Primo
;Coppolino F.;De Gaetano G. V.;Tavella L.;Petrungaro A.;Quartarone E.;Teti G.;Beninati C.;Lentini G.
Ultimo
2026-01-01
Abstract
The clinical application of RNA-targeting therapeutics is frequently limited by unpredictable innate immune activation, which can affect both safety and efficacy. Therefore, the development of robust platforms to assess drug-induced innate immune responses is crucial for the early evaluation of these compounds. Here, we developed a whole-blood assay for the assessment of innate immune activation induced by RNA-targeting therapeutics. The platform was evaluated using Food and Drug Administration (FDA)-approved drugs and compounds previously withdrawn or discontinued due to immune-related adverse effects. The assay showed qualitative concordance with known clinical immunogenicity profiles, with compounds associated with immune-related toxicities inducing stronger immune responses than therapeutics with established clinical safety records. Integrated cytokine analysis identified IL-8 and CXCL10 as candidate biomarkers of immune activation, enabling compound characterization according to their immunostimulatory profiles. Parallel studies in murine whole blood provided cross-species comparisons highlighting species-specific differences in innate immune responses. To investigate nucleic acid-sensing pathways contributing to innate immune activation, we applied the assay to transgenic mouse strains deficient in key signaling molecules, including MAVS, MyD88, TRIF, and UNC93B1, supporting their involvement in RNA-induced inflammatory responses. Collectively, our assay supports comparative profiling of innate immune activation to RNA-targeting therapeutics, with potential utility in the early evaluation of next-generation RNA therapies.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


